questionText: To ask the Secretary of State for Health and Social Care, if he will make an assessment of the potential merits of requiring NHS England to establish an agreement in principle with pharmaceutical companies that commercial flexibility may be granted for a multi-indication medicine pending the outcome of the National Institute for Health and Care Excellence evaluation of such medicines.
answerText: Indication-specific pricing can support access to treatments, including for rare conditions, by enabling companies to propose a specific price for smaller indications that would otherwise be commercially unviable under a uniform price.In January 2025, fol...
heading: Drugs: Licensing